Defunct Company
Total Trials
8
As Lead Sponsor
As Collaborator
0
Total Enrollment
1,325
NCT02834741
Safety, Tolerability, PK of Oral NYX-2925 in Healthy Volunteers
Phase: Phase 1
Role: Lead Sponsor
Start: Jul 31, 2016
Completion: Mar 31, 2017
NCT03219320
Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
Phase: Phase 2
Start: Jun 27, 2017
Completion: Nov 2, 2018
NCT03249103
Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia
Start: Aug 14, 2017
Completion: Apr 18, 2019
NCT04044664
Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder
Start: Jan 25, 2019
Completion: Aug 5, 2020
NCT04146896
Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN)
Start: Nov 12, 2019
Completion: Feb 23, 2022
NCT04147858
Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia
Completion: Jun 16, 2022
NCT04148391
NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)
Start: Nov 14, 2019
Completion: Dec 30, 2022
NCT05181995
Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSD
Phase: Phase 2/3
Start: Dec 13, 2021
Completion: Mar 30, 2023